Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes

Purpose Our aim was to investigate the effects of the sodium glucose cotransporter 2 inhibitor empagliflozin on urinary and serum glucose and electrolytes, urinary volume, osmolality, and the renin−angiotensin system in patients with type 2 diabetes. Methods In an open-label study, 22 patients receiving metformin (median age 56 years; range 40–65 years) received empagliflozin 25 mg once daily for 5 days. Food, fluid, and sodium intake were...